阿帕达姆塔斯阿尔法:第一次批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|February 28, 2024
概括
复合ADAMTS13酶阿帕达马酶α现在已在美国批准用于治疗先天性血栓性血栓性缺血性紫外线 (TTP). 这标志着对TTP患者的酶替代疗法的重大进展.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血栓性血栓塞性紫外线 (TTP) 是一种罕见的血液疾病,其特征是微血管病性血清性贫血,血栓塞性衰竭和器官损伤.
- 缺少ADAMTS13 (一种具有血栓胺基因的分解蛋白和金属蛋白酶13) 是先天性TTP的根本原因.
- 目前对先天性TTP的治疗选择有限,这凸显了需要有效的酶替代疗法.
研究的目的:
- 总结一下阿帕达马酶α的发展里程碑,这是一个重组ADAMTS13酶.
- 值得强调的是,美国FDA最近批准了阿帕达马酶α用于先天性TTP.
- 为其他TTP形式和状细胞疾病提供正在进行的临床开发的概述.
主要方法:
- 对阿帕达玛酶α的临床前和临床开发数据的审查.
- 对监管提交和批准流程的分析.
- 治疗应用和正在进行的研究的总结.
主要成果:
- 阿帕达马酶α (复合-krhn;ADZYNMA) 是人类复合形式的ADAMTS13.
- 2023年11月9日,阿帕达马酶α获得美国FDA的批准,用于先天性TTP的预防性和按需酶替代疗法 (ERT).
- 该药物还在欧盟和日本对先天性TTP进行监管审查,并针对免疫介导的TTP和状细胞疾病进行临床开发.
结论:
- 美国对阿帕达马酶α的批准代表了先天性TTP患者的显著治疗进步.
- 阿帕达马酶α为管理TTP提供了一个新的酶替代疗法选择.
- 目前正在进行进一步的临床开发,以探索其在其他相关血液病症中的有效性.
相关概念视频
RNA Editing
10.2K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
10.2K
Experimental RNAi
8.4K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.4K
Adrenergic Receptors: ɑ Subtype
3.3K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.3K
Adrenergic Agonists: Direct-Acting Agents
3.1K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
3.1K
Adrenergic Agonists: Therapeutic Uses
2.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.2K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K


